National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 1419355

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 6/25/2021

VAERS ID: 1419355
VAERS Form:2
Age:89.0
Sex:Female
Location:Foreign
Vaccinated:2021-06-05
Onset:2021-06-05
Submitted:0000-00-00
Entered:2021-06-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH FD1921 / 2 - / OT

Administered by: Other      Purchased by: ??
Symptoms: Asthenia, Sinus bradycardia

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2021-06-05
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: FUROSEMIDE; RANEXA; LUVION [CANRENONE]
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Angina pectoris; Aortic stenosis; Decompensation cardiac; Heteroplasia
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': ITPFIZER INC2021704961

Write-up: Marked asthenia and sinus bradycardia with impossibility to assess spO2; Marked asthenia and sinus bradycardia with impossibility to assess spO2; This is a spontaneous report received from a contactable physician downloaded from the Regulatory Authority-WEB. The regulatory authority report number is IT-MINISAL02-741082. An 89-year-old female patient received bnt162b2 (COMIRNATY), intramuscular on 05Jun2021 at age of 89-year-old (Lot Number: FD1921) as dose 2, single for covid-19 immunisation. Medical history included aortic aortic stenosis, decompensation cardiac, heteroplasia all unknown if ongoing and angina pectoris. Patient received 1st dose of bnt162b2 (COMIRNATY) on 23Apr2021 via intramascular for COVID-19 vaccination and no adverse reaction. Concomitant medications included furosemide (FUROSEMIDE) taken for decompensation cardiac; ranolazine (RANEXA) taken for angina pectoris; canrenone (LUVION) taken for decompensation cardiac. The patient experienced marked asthenia and sinus bradycardia with impossibility to assess spo2 on 05Jun2021. The patient died of Marked asthenia and sinus bradycardia with impossibility to assess spO2 on 05Jun2021. It was not reported if an autopsy was performed. Clinical course: Patient suffering from serious pathologies (heart failure, pulmonary heteroplasia, severe aortic stenosis) in precarious health conditions. 1st dose of vaccine 15May2021 (as reported, pending clarification): no adverse reactions 2nd dose of vaccine 05Jun2021: marked asthenia and bradycardia on the same day. At 8.30 pm he was transported by ambulance to the hospital and died during transport. No analyzes or other tests were performed. On 08Jun2021 contacted the reporting physician for clinical report. On 10Jun2021 received clinical report, from the reporter.; Reported Cause(s) of Death: Marked asthenia and sinus bradycardia with impossibility to assess spO2; Marked asthenia and sinus bradycardia with impossibility to assess spO2

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1419355&WAYBACKHISTORY=ON


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166